Abstract:The human intestinal proton-coupled oligopeptide transporter hPEPT1 has been implicated in the absorption of pharmacologically active compounds. We have investigated the interactions between a comprehensive selection of drugs, and wild-type and variant hPEPT1s expressed in Xenopus oocytes, using radiotracer uptake and electrophysiological methods. The beta-lactam antibiotics ampicillin, amoxicillin, cephalexin and cefadroxil, the antineoplastics delta-aminolevulinic acid (delta-ALA) and bestatin, and the neuropeptide N-acetyl-Asp-Glu (NAAG), were transported, as judged by their ability to evoke inward currents. When the drugs were added in the presence of the typical substrate glycylsarcosine (Gly-Sar), the inward currents were equal or less than that induced by Gly-Sar alone. This suggests that the drugs are transported at a lower turnover rate than Gly-Sar, but may also point towards complex interactions between dipeptides, drugs and the transporter. Gly-Sar and the drugs also modified the kinetics of hPEPT1 presteady-state charge movement, by causing a reduction in maximum charge (Qmax) and a shift of the midpoint voltage (V0.5) to more negative potentials. Our results indicate that the substrate selectivity of hPEPT1 is: Gly-Sar > NAAG, delta-ALA, bestatin > cefadroxil, cephalexin > ampicillin, amoxicillin. Based on steady-state and presteady-state analysis of Gly-Sar and cefadroxil transport, we proposed an extension of the 6-state kinetic model for hPEPT1 function that globally accounts for the observed presteady-state and steady-state kinetics of neutral dipeptide and drug transport. Our model suggests that, under saturating conditions, the rate-limiting step of the hPEPT1 transport cycle is the reorientation of the empty carrier within the membrane. Variations in rates of drug cotransport are predicted to be due to differences in affinity and turnover rate. Oral availability of drugs may be reduced in the presence of physiological concentrations of dietary dipeptides in the gut, suggesting that oral delivery drugs should be taken on an empty stomach. The common hPEPT1 single-nucleotide polymorphisms Ser117Asn and Gly419Ala retained the essential kinetic and drug recognition characteristics of the wild type, suggesting that neither variant is likely to have a major impact on oral absorption of drugs.

Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease

Proton Coupled Oligopeptide Transporter 1 (PepT1) Function, Regulation, and Influence on the Intestinal Homeostasis

Biology of Peptide Transporter 2 in Mammals: New Insights into Its Function, Structure and Regulation

Transport Mechanism of Oligopeptide Transporter PepT1 and Drug Absorption Mediated by PepT1

Regulation Profile of the Intestinal Peptide Transporter 1 (Pept1)

SLC15A2 and SLC15A4 Mediate the Transport of Bacterially Derived Di/Tripeptides To Enhance the Nucleotide-Binding Oligomerization Domain-Dependent Immune Response in Mouse Bone Marrow-Derived Macrophages.

Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1

The mechanism of mammalian proton-coupled peptide transporters

Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice.

Expression, Regulation, and Role of an Oligopeptide Transporter: PEPT1 in Tumors

PepT1 Expressed in Immune Cells Has an Important Role in Promoting the Immune Response During Experimentally Induced Colitis

Functional and Molecular Expression of the Proton-Coupled Oligopeptide Transporters in Spleen and Macrophages from Mouse and Human.

Advances in Research on Prodrug Targeted to PepT1

PepT1 mediates colon damage by transporting fMLP in rats with bowel resection.

Oligopeptide/Histidine Transporter PHT1 and PHT2 — Function, Regulation, and Pathophysiological Implications Specifically in Immunoregulation

Transport Mechanisms and Functions of Peptide Transporter 2

Role of Protein Tyrosine Phosphatases in Inflammatory Bowel Disease, Celiac Disease and Diabetes: Focus on the Intestinal Mucosa

Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR

ADVANCES IN SMALL PEPTIDE TRANSPORTER GENE

Proton movement and coupling in the POT family of peptide transporters

Role of Oligopeptide Transporter PepT2 in Drug Transportation